We are honored to welcome Dr. Katharine Knobil to our Board of Directors! She has more than 20 years of experience in #biopharma research and development with expertise in #oncology and #immunology. Learn more about this exciting phase of growth here:

On this #VeteransDay, we salute the brave individuals who have served our nation with honor and courage. Thank you for your sacrifice and dedication to safeguarding our freedom.

Exciting news: @NewEnglandVC has nominated Nimbus for the 2023 NEVY Award for ‘Powerhouse Life Science Company of the Year'. Congratulations to our team, and we’re looking forward to celebrating all the #NEVYs23 nominees next month.

Another impactful day at #SITC23 as Nimbus' David Ciccone presented preclinical data on our #HPK1 inhibitor, which support the potential for best-in-class selectivity among publicly disclosed HPK1 inhibitor programs to date. More on our Ph1/2 HPK1 program:

Today at #SITC23 we presented positive preliminary dose escalation data from our Ph 1/2 #HPK1 trial, showing monotherapy benefit in 3/13 evaluable patients, including complete response in 1 patient & prolonged stable disease in 2 patients. View our poster:

Today we are sharing the first clinical data from our ongoing Phase 1/2 study of NDI-101150, our #HPK1 inhibitor in solid tumors, which will be presented at the @sitcancer Annual Meeting. Read more: #SITC23

At the #FierceBiotechSummit, Nimbus CBO @AbbasRKazimi talked about the state of play for biotech M&A and how deals with larger companies can not only move novel medicines closer to patients, but also fuel discovery and development to bring the next breakthrough medicines forward.

We are honored to be named as finalists for @Citeline's #ScripAwards2023 in the 'Licensing Deal of the Year' category. This recognition highlights our commitment to innovation through #drugdiscovery and impactful collaborations with pharma leaders like @TakedaPharma.

Happening Today: Nimbus CBO @AbbasRKazimi discusses the future of #biopharma dealmaking alongside other industry experts at the 2023 @FierceBiotech Summit. More: #FierceBiotechSummit

Tomorrow Nimbus’ David Ciccone will present preclinical data from our HPK1 inhibitor program — now in a Ph1/2 trial in #oncology — at #Targets23. Learn more: @AACR @theNCI @EORTC. More on our HPK1 clinical trial: 

Today and every day, we stand with our LGBTQIA+ colleagues, friends and family in celebrating courage, love and authenticity. Happy #NationalComingOutDay.

Today, we honor the resilience, culture and contributions of Indigenous communities in the United States. #IndigenousPeoplesDay

Nimbus CBO @AbbasRKazimi will join a panel of experts to discuss the evolving landscape of #biopharma dealmaking at the 2023 @FierceBiotech Summit. More about the #FierceBiotechSummit: 

Our Nimbi swung into action to benefit our community at the annual @LS_Cares Mini-Golf for Good event. Thank you to our friends at LSC Boston for organizing such a fun and impactful initiative each year. #LSCImpact

We are honored to receive @BiotechWkBoston's Deal of the Year Award recognizing the acquisition of our #TYK2 program and proud to share this moment with @TakedaPharma. This award recognizes our teams, deal-making and science, and honors collaboration to impact patients’ lives.

This week Chief People Officer Erin Cowhig takes the stage at @BiotechWkBoston 's DE&I Summit to share how she has built inclusive talent pipelines throughout her career. The positive impacts of diverse talent on our work to develop #breakthroughmedicines are evident every day!

Today Nimbus' Executive Director of Medicinal Chemistry, Silvana Leit, will present at the @RoySocChem 22nd Medicinal Chemistry Symposium on TAK-279 (formerly NDI-034858), a novel allosteric TYK2 inhibitor developed by Nimbus and acquired by Takeda. More:

We’re excited to announce a $210 million private financing to advance our next wave of tech-enabled small molecule medicines. Learn more:

We are honored to be a finalist for @BiotechWkBoston’s Deal of the Year Award, recognizing the acquisition of our TYK2 inhibitor by Takeda, one of the largest single asset deals in all of biotech.

This week, Nimbus' Director of Computational Chemistry, Leela Dodda, will present at the Gordon Research Conference on Medicinal Chemistry on how Nimbus uses physics-based machine learning to identify inhibitors for difficult to drug targets.